Giannini, Fiona http://orcid.org/0000-0001-6302-506X
Hogan, Alexandra B. http://orcid.org/0000-0002-6271-9921
Sarna, Mohinder http://orcid.org/0000-0002-2448-1588
Glass, Kathryn http://orcid.org/0000-0001-5905-1310
Moore, Hannah C. http://orcid.org/0000-0001-6434-8290
Funding for this research was provided by:
National Health and Medical Research Council
Stan Perron Charitable Foundation
Article History
Received: 12 December 2023
Accepted: 13 May 2024
First Online: 21 May 2024
Declarations
:
: Ethical approvals and a waiver of individual informed consent was obtained from the WA Department of Health Human Research Ethics Committee (HREC).
: Not applicable. This manuscript contains no data on individuals in any form.
: HCM has received institutional honoraria for participation in advisory group meetings on RSV epidemiology from Merck Sharp and Dohme, Pfizer and Evohealth. HCM and KG are in receipt of research funds from an Investigator-Initiated Studies Program of Merck Sharp & Dohme (Australia) Pty Ltd (not related to this study) and HCM is in receipt of research funds from Sanofi-Aventis (Australia) (not related to this study). ABH was previously engaged by Pfizer Inc to advise on modelling RSV vaccinationstrategies for which she received no financial compensation.